The proofreading exonuclease domains of the replicative DNA polymerases Pol δ and Pol ε perform an essential function in ensuring accurate DNA replication by proofreading and removing mispaired bases from the newly synthesized DNA strand.
Recent studies have shown that mutations in the proofreading domains of POLD1 and POLE (which encode the catalytic subunits of Pol δ and Pol ε, respectively, in humans) predispose to colonic polyposis and cancer, and that somatic POLE proofreading domain mutations occur in several tumour types, most commonly those of the endometrium and colorectum. Interestingly, somatic POLD1 proofreading domain mutations seem to be uncommon.
In several cases, the pathogenicity of these germline and somatic DNA polymerase proofreading domain mutations has been supported by studies using cell-free assays and Saccharomyces cerevisiae mutants, which confirm that they reduce or abolish exonuclease activity and increase the mutation rate.
Consistent with these studies, the most striking feature of tumours with somatic POLE proofreading domain mutations is their exceptional burden of base substitution mutations — 'ultramutation'. Other notable features are their characteristic mutation spectrum, with overrepresentation of C→A transversions and, in general, a strong tendency to microsatellite stability.
Endometrial cancers with somatic POLE proofreading domain mutations have an excellent prognosis, which may be because their ultramutation causes an abundance of antigenic neoepitopes, which in turn stimulate a potent antitumour immune response. The prognostic and immunological consequences of somatic POLE proofreading domain mutations in other tumour types await definition.
Future studies of DNA polymerase proofreading domain mutations in cancer may provide further insights into the mechanisms and consequences of a mutator phenotype in cancer, and help to improve care for patients with endometrial, colorectal and other cancers.
Although it has long been recognized that the exonucleolytic proofreading activity intrinsic to the replicative DNA polymerases Pol δ and Pol ε is essential for faithful replication of DNA, evidence that defective DNA polymerase proofreading contributes to human malignancy has been limited. However, recent studies have shown that germline mutations in the proofreading domains of Pol δ and Pol ε predispose to cancer, and that somatic Pol ε proofreading domain mutations occur in multiple sporadic tumours, where they underlie a phenotype of 'ultramutation' and favourable prognosis. In this Review, we summarize the current understanding of the mechanisms and consequences of polymerase proofreading domain mutations in human malignancies, and highlight the potential utility of these variants as novel cancer biomarkers and therapeutic targets.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Loeb, L. A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075–3079 (1991).
Kunkel, T. A. DNA replication fidelity. J. Biol. Chem. 279, 16895–16898 (2004).
Loeb, L. A. & Monnat, R. J. DNA polymerases and human disease. Nat. Rev. Genet. 9, 594–604 (2008).
Morrison, A., Johnson, A. L., Johnston, L. H. & Sugino, A. Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J. 12, 1467–1473 (1993).
Edelmann, W. et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91, 467–477 (1997).
Albertson, T. M. et al. DNA polymerase ε and δ proofreading suppress discrete mutator and cancer phenotypes in mice. Proc. Natl Acad. Sci. USA 106, 17101–17104 (2009). Demonstration that although both Pole and Pold1 exonuclease-null mice develop tumours, the tumour spectrum differs between the two mutant alleles.
Goldsby, R. E. et al. High incidence of epithelial cancers in mice deficient for DNA polymerase δ proofreading. Proc. Natl Acad. Sci. USA 99, 15560–15565 (2002).
Goldsby, R. E. et al. Defective DNA polymerase-δ proofreading causes cancer susceptibility in mice. Nat. Med. 7, 638–639 (2001).
Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027–1038 (1993).
Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812–816 (1993).
Yoshida, R. et al. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur. J. Hum. Genet. 19, 320–325 (2011).
Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144 (2012). Identification of germline POLE and POLD1 proofreading domain mutations in patients with intestinal polyposis and CRC.
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Erson-Omay, E. Z. et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro Oncol. 17, 1356–1364 (2015).
Church, D. N. et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum. Mol. Genet. 22, 2820–2828 (2013).
Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660–664 (2012).
The Cancer Genome Atlas Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013). Demonstration that ECs with somatic POLE proofreading domain mutations are ultramutated and may have a favourable prognosis.
Shinbrot, E. et al. Exonuclease mutations in DNA polymerase ε reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 24, 1740–1750 (2014). Comprehensive analysis of TCGA sequencing data to identify pathogenic somatic polymerase proofreading domain mutations across multiple tumour types.
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013). Pan-cancer analysis demonstrating that the POLE proofreading domain-mutant mutational signature is present in 0.5% of tumours.
Church, D. N. et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J. Natl Cancer Inst. 107, 1–8 (2015).
Billingsley, C. C. et al. Polymerase ε (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121, 386–394 (2014).
Stelloo, E. et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod. Pathol. 28, 836–844 (2015).
Talhouk, A. et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer 113, 299–310 (2015).
Meng, B. et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol. Oncol. 134, 15–19 (2014).
van Gool, I. C. et al. POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer. Clin. Cancer Res. 21, 3347–3355 (2015). First demonstration that somatic POLE proofreading domain mutations are associated with a cytotoxic T cell response.
Howitt, B. E. et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1, 1319–1323 (2015).
Henninger, E. E. & Pursell, Z. F. DNA polymerase ε and its roles in genome stability. IUBMB Life 66, 339–351 (2014).
Prindle, M. J. & Loeb, L. A. DNA polymerase delta in DNA replication and genome maintenance. Env. Mol. Mutag. 53, 666–682 (2012).
Pavlov, Y. I. & Shcherbakova, P. V. DNA polymerases at the eukaryotic fork—20 years later. Mutat. Res. 685, 45–53 (2010).
Johansson, E. & Dixon, N. Replicative DNA polymerases. Cold Spring Harb. Perspect. Biol. 5, a012799 (2013).
Morrison, A., Araki, H., Clark, A. B., Hamatake, R. K. & Sugino, A. A third essential DNA polymerase in S. cerevisiae. Cell 62, 1143–1151 (1990).
Budd, M. & Campbell, J. L. Temperature-sensitive mutations in the yeast DNA polymerase I gene. Proc. Natl Acad. Sci. USA 84, 2838–2842 (1987).
Budd, M. E. & Campbell, J. L. DNA polymerases δ and ε are required for chromosomal replication in Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 496–505 (1993).
Francesconi, S., Park, H. & Wang, T. S. Fission yeast with DNA polymerase δ temperature-sensitive alleles exhibits cell division cycle phenotype. Nucleic Acids Res. 21, 3821–3828 (1993).
Bernad, A., Blanco, L., Lázaro, J., Martín, G. & Salas, M. A conserved 3′→5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59, 219–228 (1989).
Shevelev, I. V. & Hübscher, U. The 3′ 5′ exonucleases. Nat. Rev. Mol. Cell Biol. 3, 364–376 (2002).
Baranovskiy, A. G. et al. X-ray structure of the complex of regulatory subunits of human DNA polymerase δ. Cell Cycle 7, 3026–3036 (2008).
Podust, V. N., Chang, L. S., Ott, R., Dianov, G. L. & Fanning, E. Reconstitution of human DNA polymerase δ using recombinant baculoviruses: the p12 subunit potentiates DNA polymerizing activity of the four-subunit enzyme. J. Biol. Chem. 277, 3894–3901 (2002).
Zhou, Y., Meng, X., Zhang, S., Lee, E. Y. & Lee, M. Y. Characterization of human DNA polymerase δ and its subassemblies reconstituted by expression in the MultiBac system. PLoS ONE 7, e319156 (2012).
Garbacz, M. et al. Fidelity consequences of the impaired interaction between DNA polymerase ε and the GINS complex. DNA Repair 29, 23–35 (2015).
Langston, L. D. et al. CMG helicase and DNA polymerase ε form a functional 15-subunit holoenzyme for eukaryotic leading-strand DNA replication. Proc. Natl Acad. Sci. USA 111, 15390–15395 (2014).
Sengupta, S., van Deursen, F., de Piccoli, G. & Labib, K. Dpb2 integrates the leading-strand DNA polymerase into the eukaryotic replisome. Curr. Biol. 23, 543–552 (2013).
Aksenova, A. et al. Mismatch repair-independent increase in spontaneous mutagenesis in yeast lacking non-essential subunits of DNA polymerase ε. PLoS Genet. 6, e1001209 (2010).
Pursell, Z. F., Isoz, I., Lundström, E.-B., Johansson, E. & Kunkel, T. A. Yeast DNA polymerase ε participates in leading-strand DNA replication. Science 317, 127–130 (2007). Demonstration that Pol ε replicates the leading strand in S. cerevisiae.
McElhinny, S. A., Gordenin, D. A., Stith, C. M., Burgers, P. M. J. & Kunkel, T. A. Division of labor at the eukaryotic replication fork. Mol. Cell 30, 137–144 (2008).
Miyabe, I., Kunkel, T. A. & Carr, A. M. The major roles of DNA polymerases ε and δ at the eukaryotic replication fork are evolutionarily conserved. PLoS Genet. 7, e1002407 (2011).
Vazquez, E. & Antequera, F. Replication dynamics in fission and budding yeasts through DNA polymerase tracking. Bioessays 37, 1067–1073 (2015).
Georgescu, R. E. et al. Reconstitution of a eukaryotic replisome reveals suppression mechanisms that define leading/lagging strand operation. eLife 4, e04988 (2015).
Georgescu, R. E. et al. Mechanism of asymmetric polymerase assembly at the eukaryotic replication fork. Nat. Struct. Mol. Biol. 21, 664–670 (2014).
Hogg, M. et al. Structural basis for processive DNA synthesis by yeast DNA polymerase ε. Nat. Struct. Mol. Biol. 21, 49–55 (2014). First report of the crystal structure of the S. cerevisiae Pol ε catalytic subunit.
Johnson, Robert, E., Klassen, R., Prakash, L. & Prakash, S. A major role of DNA polymerase δ in replication of both the leading and lagging DNA strands. Mol. Cell 59, 163–175 (2015).
Blank, A., Kim, B. Fau-Loeb, L. A. & Loeb, L. A. DNA polymerase δ is required for base excision repair of DNA methylation damage in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 91, 9047–9051 (1994).
Stucki, M. et al. Mammalian base excision repair by DNA polymerases δ and ε. Oncogene 17, 835–843 (1998).
Nishida, C., Reinhard, P. & Linn, S. DNA repair synthesis in human fibroblasts requires DNA polymerase δ. J. Biol. Chem. 263, 501–510 (1988).
Lehmann, A. R. DNA polymerases and repair synthesis in NER in human cells. DNA Repair 10, 730–733 (2011).
Tran, H. T., Gordenin, D. A. & Resnick, M. A. The 3′→5′ exonucleases of DNA polymerases δ and ε and the 5′→3′ exonuclease Exo1 have major roles in postreplication mutation avoidance in Saccharomyces cerevisiae. Mol. Cell. Biol. 19, 2000–2007 (1999).
Bowen, N. et al. Reconstitution of long and short patch mismatch repair reactions using Saccharomyces cerevisiae proteins. Proc. Natl Acad. Sci. USA 110, 18472–18477 (2013).
Zhang, Y. et al. Reconstitution of 5′-directed human mismatch repair in a purified system. Cell 122, 693–705 (2005).
Costantino, L. et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 343, 88–91 (2014).
Lydeard, J. R., Jain, S., Yamaguchi, M. & Haber, J. E. Break-induced replication and telomerase-independent telomere maintenance require Pol32. Nature 448, 820–823 (2007).
Pursell, Z. F. & Kunkel, T. A. DNA polymerase ε: a polymerase of unusual size (and complexity). Prog. Nucleic Acid Res. Mol. Biol. 82, 101–145 (2008).
Ganai, R. a., Bylund, G. O. & Johansson, E. Switching between polymerase and exonuclease sites in DNA polymerase ε. Nucleic Acids Res. 4, 1–11 (2014).
Simon, M., Giot, L. & Faye, G. The 3′ to 5′ exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication. EMBO J. 10, 2165–2170 (1991).
Murphy, K., Darmawan, H., Schultz, A., da Silva, E. F. & Reha-Krantz, L. J. A method to select for mutator DNA polymerase δs in Saccharomyces cerevisiae. Genome 49, 403–410 (2006).
Datta, A. et al. Checkpoint-dependent activation of mutagenic repair in Saccharomyces cerevisiae pol3-01 mutants. Mol. Cell 6, 593–603 (2000).
Williams, L. N. et al. dNTP pool levels modulate mutator phenotypes of error-prone DNA polymerase ε variants. Proc. Natl Acad. Sci. USA 112, E2457–E2466 (2015).
Bellido, F. et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet. Med. https://dx.doi.org/10.1038/gim.2015.75 (2015).
Spier, I. et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int. J. Cancer 137, 320–331 (2015).
Chubb, D. et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J. Clin. Oncol. 33, 426–432 (2015).
Valle, L. et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum. Mol. Genet. 23, 3506–3512 (2014).
Elsayed, F. A. et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur. J. Hum. Genet. 23, 1080–1084 (2015).
Rohlin, A. et al. A mutation in POLE predisposing to a multi-tumour phenotype. Int. J. Oncol. 45, 77–81 (2014).
Hansen, M. F. et al. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam. Cancer 14, 437–448 (2015).
Aoude, L. G. et al. POLE mutations in families predisposed to cutaneous melanoma. Fam. Cancer 14, 621–628 (2015).
Zou, Y. et al. Frequent POLE1 p. S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutat. Res. 761, 49–52 (2014).
Jones, S. et al. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat. Commun. 5, 5006 (2014).
Shlien, A. et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat. Genet. 47, 257–262 (2015). Demonstration that acquisition of pathogenic POLD1 and POLE proofreading domain mutations is associated with rapid tumour growth in patients with CMMR-D.
The Cancer Genome Atlas Network. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91–101 (2014).
The Cancer Genome Atlas Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012).
The Cancer Genome Atlas Network. Comprehensive molecular profiling of lung adenocarcinomas. Nature 511, 543–550 (2014).
Kane, D. P. & Shcherbakova, P. V. A common cancer-associated DNA polymerase ε mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 74, 1895–1901 (2014).
Hussein, Y. R. et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod. Pathol. 28, 505–514 (2014).
Bertagnolli, M. M. et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer—a study of CALGB 9581 and 89803. J. Clin. Oncol. 29, 3153–3162 (2011).
Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261–1270 (2011).
Nelson, G. S. et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol. Oncol. 131, 309–314 (2013).
Diaz-Padilla, I. et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 88, 154–167 (2013).
Heitzer, E. & Tomlinson, I. Replicative DNA polymerase mutations in cancer. Curr. Opin. Genet. Dev. 24, 107–113 (2014).
Williams, L. N., Herr, A. J. & Preston, B. D. Emergence of DNA polymerase ε antimutators that escape error-induced extinction in yeast. Genetics 193, 751–770 (2013).
Herr, A. J., Kennedy, S. R., Knowels, G. M., Schultz, E. M. & Preston, B. D. DNA replication error-induced extinction of diploid yeast. Genetics 196, 677–691 (2014).
Heyer, J., Yang, K., Lipkin, M., Edelmann, W. & Kucherlapati, R. Mouse models for colorectal cancer. Oncogene 18, 5325–5333 (1999).
Sole, R. V. & Deisboeck, T. S. An error catastrophe in cancer? J. Theor. Biol. 228, 47–54 (2004).
Loeb, L. A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer 11, 450–457 (2011).
Herr, A. J. et al. Mutator suppression and escape from replication error-induced extinction in yeast. PLoS Genet. 7, e1002282 (2011).
Ghodgaonkar, M. M. et al. Phenotypic characterization of missense polymerase-δ mutations using an inducible protein-replacement system. Nat. Commun. 5, 4990–4990 (2014).
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Korona, D. A., LeCompte, K. G. & Pursell, Z. F. The high fidelity and unique error signature of human DNA polymerase. Nucleic Acids Res. 39, 1763–1773 (2011).
Schwarz, J. M., Cooper, D. N. Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361–362 (2014).
Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073–1081 (2009).
Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).
Fox, E. J., Prindle, M. J. & Loeb, L. A. Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev. 32, 353–361 (2013).
Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43–51 (2015).
McFarland, C. D., Mirny, L. A. & Korolev, K. S. Tug-of-war between driver and passenger mutationsin cancer and other adaptive processes. Proc. Natl Acad. Sci. USA 111, 15138–15143 (2014).
Vasen, H. F. et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62, 812–823 (2013).
Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
Jin, Y. H. et al. Cadmium is a mutagen that acts by inhibiting mismatch repair. Nat. Genet. 34, 326–329 (2003).
Mertz, T. M., Sharma, S., Chabes, A. & Shcherbakova, P. V. Colon cancer-associated mutator DNA polymerase δ variant causes expansion of dNTP pools increasing its own infidelity. Proc. Natl Acad. Sci. USA 112, E2467–E2476 (2015).
Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).
Loeb, L. A., Bielas, J. H. & Beckman, R. A. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68, 3551–3557 (2008).
Swan, M. K., Johnson, R. E., Prakash, L., Prakash, S. & Aggarwal, A. K. Structural basis of high-fidelity DNA synthesis by yeast DNA polymerase δ. Nat. Struct. Mol. Biol. 16, 979–986 (2009).
Wang, J., Yu, P., Lin, T. C., Konigsberg, W. H. & Steitz, T. A. Crystal structures of an NH2-terminal fragment of T4 DNA polymerase and its complexes with single-stranded DNA and with divalent metal ions. Biochemistry 35, 8110–8119 (1996).
Hoang, L. N. et al. Polymerase epsilon exonuclease domain mutations in ovarian endometrioid carcinoma. Int. J. Gynecol. Cancer 25, 1187–1193 (2015).
Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2014).
Abdus Sattar, A. K., Lin, T. C., Jones, C. & Konigsberg, W. H. Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry 35, 16621–16629 (1996).
Stenzinger, A. et al. Mutations in POLE and survival of colorectal cancer patients — link to disease stage and treatment. Cancer Med. 3, 1527–1538 (2014).
The authors thank J. Grimes for help in generating the Pol δ and Pol ε structures and N. de Wind for helpful comments on the manuscript. Work in the host laboratories is supported by an Academy of Medical Sciences/Health Foundation Clinician Scientist Fellowship Award (to D.N.C.), Cancer Research UK (programme grant C6199/A10417 to I.T.), the European Research Council (EVOCAN grant agreement: 340560 to I.T.), the Dutch Cancer Society (grant ref: UL2012-5719 to T.B.) and the Medical Research Council (grant Ref. MR/L016591/1 to S.E.K.) and core funding to the Wellcome Trust Centre for Human Genetics from the Wellcome Trust (ref: 090532/Z/09/Z). D.N.C. has received funding from the Oxford Cancer Centre, UK.
The authors declare no competing financial interests.
- Mismatch repair
(MMR). A mechanism of post-replicative DNA repair that removes mismatched bases and small insertions and deletions (indels) from the newly synthesized DNA strand.
Describes tumours with an exceptional frequency of mutations, often exceeding 100 mutations per megabase and often caused by mutations in the gene encoding the catalytic subunit of DNA polymerase ε (POLE).
Novel epitopes, created by somatic mutations in tumours, that are capable of eliciting an antitumour immune response.
- B family polymerases
Replicative and repair DNA polymerases that are grouped on the basis of sequence and structural similarities, and include the prokaryotic DNA polymerase Pol II, and the eukaryotic DNA polymerases Pol ζ, Pol α, Pol δ and Pol ε.
A multiprotein complex essential for eukaryotic DNA replication. The name is derived from the Japanese go, ichi, ni and san (meaning five, one, two and three), and refers to the constituent components in budding yeast: Sld5, Psf1, Psf2 and Psf3.
- Mutator phenotype
Elevation of the mutation rate above that expected for normally dividing cells. It has been argued that the acquisition of a mutator phenotype is a characteristic of many cancers.
Absence of small insertions and deletions (indels) at repetitive DNA microsatellites as a result of proficient DNA mismatch repair.
- Intestinal polyposis
A phenotype of multiple colonic polyps and increased risk of colorectal cancer that may be due to a germline mutation in a known predisposition gene (for example, adenomatous polyposis coli (APC) or MUTYH) or may lack an obvious genetic cause.
- Mutational hot spot
A genomic region that is the site of mutations in cancers at a frequency greater than that expected by chance: for example, codon 600 in the serine/threonine kinase BRAF.
- Multinucleated giant cells
Abnormally large cells with multiple nuclei and typically bizarre morphology that are observed in association with chronic inflammation and some types of malignancy.
- Microsatellite instability
(MSI). The presence of small insertions and deletions (indels) at repetitive DNA microsatellites that result from defective DNA mismatch repair.
- Synthetically lethal
A type of genetic interaction in which the combination of mutations in two genes results in cell death, whereas cells harbouring only one of the mutations are viable.
- Antimutator mutations
Mutations that result in an increase in the fidelity of DNA replication; examples have been reported in both Escherichia coli and Saccharomyces cerevisiae, although their occurrence in human cancer is currently not proved.
- Polymerase proofreading-associated polyposis
(PPAP). A high-penetrance, dominantly inherited condition characterized by multiple colorectal adenomas and carcinomas, caused by germline mutations in the genes encoding the catalytic subunits of the DNA polymerases Pol δ and Pol ε (POLD1 and POLE, respectively).
- Lynch syndrome
A tumour predisposition syndrome caused by germline mutation of mismatch repair genes, which manifests as increased risk of carcinomas of the colon and rectum, endometrium, ovary, stomach and several other organs.
- MUTYH-associated polyposis
A syndrome characterized by multiple intestinal adenomas and an increased risk of colorectal carcinoma. It is caused by germline mutations in the base excision repair gene MUTYH.
- Basket trial
Also known as a bucket trial. A study in which patients with a specific molecular marker are recruited for treatment with a corresponding targeted therapy, irrespective of tumour histology or tissue of origin.
About this article
Cite this article
Rayner, E., van Gool, I., Palles, C. et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer 16, 71–81 (2016). https://doi.org/10.1038/nrc.2015.12
The orphan nuclear receptor NR0B2 could be a novel susceptibility locus associated with microsatellite‐stable, APC mutation‐negative early‐onset colorectal carcinomas with metabolic manifestation
Genes, Chromosomes and Cancer (2021)
POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting
International Journal of Gynecological Pathology (2021)
Trends in Genetics (2021)
Identification of a metabolic-related gene signature predicting the overall survival for patients with stomach adenocarcinoma
The Journal of Pathology (2021)